Bifeprunox is a potent dopamine D2-like and 5-HT1A receptor partial agonist with pK_is of 7.19 and 8.83 for cortex 5-HT1A and striatum D2, and a pEC₅₀ of 6.37 for hippocampus 5-HT1A, respectively. Bifeprunox is an antipsychotic for the research of schizophrenia^[1][2]. IC50 & Target: pKi: 7.19 (cortex 5-HT1A) and 8.83 (striatum D2)^[2]
pEC50: 6.37 (hippocampus 5-HT1A)^[2] In Vitro: Bifeprunox has a pK_i of 8 at h5-HT1A receptors, with an E_max of 70%^[1]. In Vivo: Bifeprunox (0.001-2.5 mg/kg) reduces marble burying in mice^[2].
Bifeprunox (4-250μg/ kg) influences nicotine-seeking behaviour in response to drug-associated stimuli in rats^[3].